Tarsus Pharmaceuticals, Inc. TARS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $535.08M+129% | $451.36M+147% | $366.1M+182% | $295.52M+254% | $233.67M+449% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $72.26M+29.7% | $64.32M+20.5% | $63.16M+26.8% | $59M+18.5% | $55.73M+11.4% | ||
| $478.76M+76.8% | $427.32M+80.1% | $365.67M+87.1% | $314.95M+91.2% | $270.73M+103% | ||
| $585.89M+70.9% | $522.33M+72.1% | $453.51M+67.8% | $393.57M+64.2% | $342.84M+72.8% | ||
| -$50.81M+53.5% | -$70.97M+41.1% | -$87.41M+37.8% | -$98.05M+37.3% | -$109.17M+30.0% | ||
| -9.5%+37.2pp | -15.7%+50.2pp | -23.9%+84.6pp | -33.2%+154pp | -46.7%+320pp | ||
| $8.85M-2.5% | $8.94M+13.8% | $9.03M+38.4% | $9.21M+86.5% | $9.08M+149% | ||
| $6.96M+64.8% | $6.61M+31.8% | $6.26M0.0% | $6.05M-3.9% | $4.22M-45.1% | ||
| —— | -$64.36M+44.3% | -$77.16M+36.0% | -$89.96M+28.4% | -$102.76M+21.4% | ||
| —— | —— | —— | —— | $0— | ||
| -$48.27M+54.0% | -$66.42M+42.5% | -$81.16M+39.6% | -$91.99M+38.7% | -$104.94M+29.2% | ||
| -9%+35.9pp | -14.7%+48.4pp | -22.2%+81.5pp | -31.1%+149pp | -44.9%+303pp | ||
| -$1.13+58.5% | -$1.61+47.9% | -$2.01+46.7% | -$2.32+47.7% | -$2.72+42.5% | ||
| -$49.13M+54.4% | -$69.27M+42.0% | -$85.72M+38.5% | -$96.46M+37.9% | -$107.77M+30.4% | ||
| -9.2%+36.9pp | -15.3%+49.9pp | -23.4%+84.2pp | -32.6%+154pp | -46.1%+318pp | ||
| -$50.81M+53.5% | -$70.97M+41.1% | -$87.41M+37.8% | -$98.05M+37.3% | -$109.17M+30.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s revenue?
- Tarsus Pharmaceuticals, Inc. (TARS) generated $535.1M in revenue over the trailing twelve months, up 129.0% year over year.
- Is Tarsus Pharmaceuticals, Inc. profitable?
- Tarsus Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $48.3M over the trailing twelve months, a -9.0% net margin.
- What are Tarsus Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 42.7% and operating margin is -9.5%, with a -9.0% net margin.
- What is Tarsus Pharmaceuticals, Inc.'s earnings per share?
- Tarsus Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-1.13.
- Where does Tarsus Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
